Cargando…
Good response to neoadjuvant chemoradiotherapy predicts good oncological outcome in locally advanced rectal cancer
BACKGROUND: After pre-operative concurrent long course chemoradiotherapy (CRT), pathologic complete response (pCR) has been reported with better oncologic outcomes in many articles, whether a moderate response (TRG1) can translate into good clinical outcome remains uncertain. METHODS: A total of 132...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799075/ https://www.ncbi.nlm.nih.gov/pubmed/35116744 http://dx.doi.org/10.21037/tcr.2019.01.17 |
_version_ | 1784641980694790144 |
---|---|
author | Zhang, Chi Xu, Liping Qin, Qin Liu, Jia Tang, Xinyu Jiang, Nan Zhang, Zhaoyue Li, Fei Cheng, Hongyan Chen, Jiayan Sun, Xinchen |
author_facet | Zhang, Chi Xu, Liping Qin, Qin Liu, Jia Tang, Xinyu Jiang, Nan Zhang, Zhaoyue Li, Fei Cheng, Hongyan Chen, Jiayan Sun, Xinchen |
author_sort | Zhang, Chi |
collection | PubMed |
description | BACKGROUND: After pre-operative concurrent long course chemoradiotherapy (CRT), pathologic complete response (pCR) has been reported with better oncologic outcomes in many articles, whether a moderate response (TRG1) can translate into good clinical outcome remains uncertain. METHODS: A total of 132 locally advanced rectal cancer patients with neoadjuvant chemoradiotherapy followed by radical surgery were recruited. Their clinicopathologic characteristics and clinical records were retrospectively reviewed. The association between clinicopathologic parameters and pathological response was conducted, and the multivariable analysis of the association between pathologic response and survival was performed. RESULTS: With a median follow-up of 21.5 months, gender was the only factor associated with pCR (TRG0), while dual-agent chemotherapy regimen was linked with a lower likelihood of good response (TRG0-1). Good response (TGR0-1) remained significant associated with overall survival (OS) and disease-free survival (DFS) after multivariate adjustment. TRG1 was linked with better DFS compared with TRG2-3. CONCLUSIONS: Patients with post-CRT good response (TRG0-1) demonstrate an excellent local and remote control, especially with those non-pCR patients (TRG1) getting better outcomes. |
format | Online Article Text |
id | pubmed-8799075 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-87990752022-02-02 Good response to neoadjuvant chemoradiotherapy predicts good oncological outcome in locally advanced rectal cancer Zhang, Chi Xu, Liping Qin, Qin Liu, Jia Tang, Xinyu Jiang, Nan Zhang, Zhaoyue Li, Fei Cheng, Hongyan Chen, Jiayan Sun, Xinchen Transl Cancer Res Original Article BACKGROUND: After pre-operative concurrent long course chemoradiotherapy (CRT), pathologic complete response (pCR) has been reported with better oncologic outcomes in many articles, whether a moderate response (TRG1) can translate into good clinical outcome remains uncertain. METHODS: A total of 132 locally advanced rectal cancer patients with neoadjuvant chemoradiotherapy followed by radical surgery were recruited. Their clinicopathologic characteristics and clinical records were retrospectively reviewed. The association between clinicopathologic parameters and pathological response was conducted, and the multivariable analysis of the association between pathologic response and survival was performed. RESULTS: With a median follow-up of 21.5 months, gender was the only factor associated with pCR (TRG0), while dual-agent chemotherapy regimen was linked with a lower likelihood of good response (TRG0-1). Good response (TGR0-1) remained significant associated with overall survival (OS) and disease-free survival (DFS) after multivariate adjustment. TRG1 was linked with better DFS compared with TRG2-3. CONCLUSIONS: Patients with post-CRT good response (TRG0-1) demonstrate an excellent local and remote control, especially with those non-pCR patients (TRG1) getting better outcomes. AME Publishing Company 2019-02 /pmc/articles/PMC8799075/ /pubmed/35116744 http://dx.doi.org/10.21037/tcr.2019.01.17 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
spellingShingle | Original Article Zhang, Chi Xu, Liping Qin, Qin Liu, Jia Tang, Xinyu Jiang, Nan Zhang, Zhaoyue Li, Fei Cheng, Hongyan Chen, Jiayan Sun, Xinchen Good response to neoadjuvant chemoradiotherapy predicts good oncological outcome in locally advanced rectal cancer |
title | Good response to neoadjuvant chemoradiotherapy predicts good oncological outcome in locally advanced rectal cancer |
title_full | Good response to neoadjuvant chemoradiotherapy predicts good oncological outcome in locally advanced rectal cancer |
title_fullStr | Good response to neoadjuvant chemoradiotherapy predicts good oncological outcome in locally advanced rectal cancer |
title_full_unstemmed | Good response to neoadjuvant chemoradiotherapy predicts good oncological outcome in locally advanced rectal cancer |
title_short | Good response to neoadjuvant chemoradiotherapy predicts good oncological outcome in locally advanced rectal cancer |
title_sort | good response to neoadjuvant chemoradiotherapy predicts good oncological outcome in locally advanced rectal cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799075/ https://www.ncbi.nlm.nih.gov/pubmed/35116744 http://dx.doi.org/10.21037/tcr.2019.01.17 |
work_keys_str_mv | AT zhangchi goodresponsetoneoadjuvantchemoradiotherapypredictsgoodoncologicaloutcomeinlocallyadvancedrectalcancer AT xuliping goodresponsetoneoadjuvantchemoradiotherapypredictsgoodoncologicaloutcomeinlocallyadvancedrectalcancer AT qinqin goodresponsetoneoadjuvantchemoradiotherapypredictsgoodoncologicaloutcomeinlocallyadvancedrectalcancer AT liujia goodresponsetoneoadjuvantchemoradiotherapypredictsgoodoncologicaloutcomeinlocallyadvancedrectalcancer AT tangxinyu goodresponsetoneoadjuvantchemoradiotherapypredictsgoodoncologicaloutcomeinlocallyadvancedrectalcancer AT jiangnan goodresponsetoneoadjuvantchemoradiotherapypredictsgoodoncologicaloutcomeinlocallyadvancedrectalcancer AT zhangzhaoyue goodresponsetoneoadjuvantchemoradiotherapypredictsgoodoncologicaloutcomeinlocallyadvancedrectalcancer AT lifei goodresponsetoneoadjuvantchemoradiotherapypredictsgoodoncologicaloutcomeinlocallyadvancedrectalcancer AT chenghongyan goodresponsetoneoadjuvantchemoradiotherapypredictsgoodoncologicaloutcomeinlocallyadvancedrectalcancer AT chenjiayan goodresponsetoneoadjuvantchemoradiotherapypredictsgoodoncologicaloutcomeinlocallyadvancedrectalcancer AT sunxinchen goodresponsetoneoadjuvantchemoradiotherapypredictsgoodoncologicaloutcomeinlocallyadvancedrectalcancer |